In 2019, the FDA authorised a whole new nasal spray medication named esketamine (Spravato), a form of ketamine, for use with the oral antidepressant for individuals with significant depressive condition (MDD) who have treatment-resistant depression. This announcement outlined the very first copyright-like drug to be approved for lawful use; Other f… Read More